These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 9201663)

  • 1. Long-term follow-up of gender-specific outcomes after thrombolytic therapy for acute myocardial infarction from the GUSTO-I trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
    Moen EK; Asher CR; Miller DP; Weaver WD; White HD; Califf RM; Topol EJ
    J Womens Health; 1997 Jun; 6(3):285-93. PubMed ID: 9201663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators.
    Weaver WD; White HD; Wilcox RG; Aylward PE; Morris D; Guerci A; Ohman EM; Barbash GI; Betriu A; Sadowski Z; Topol EJ; Califf RM
    JAMA; 1996 Mar; 275(10):777-82. PubMed ID: 8598594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early reinfarction after fibrinolysis: experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUSTO III) trials.
    Hudson MP; Granger CB; Topol EJ; Pieper KS; Armstrong PW; Barbash GI; Guerci AD; Vahanian A; Califf RM; Ohman EM
    Circulation; 2001 Sep; 104(11):1229-35. PubMed ID: 11551872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coronary revascularization surgery after myocardial infarction: impact of bypass surgery on survival after thrombolysis. GUSTO Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
    Tardiff BE; Califf RM; Morris D; Bates E; Woodlief LH; Lee KL; Green C; Rutsch W; Betriu A; Aylward PE; Topol EJ
    J Am Coll Cardiol; 1997 Feb; 29(2):240-9. PubMed ID: 9014973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction: results from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III Trial.
    Topol EJ; Ohman EM; Armstrong PW; Wilcox R; Skene AM; Aylward P; Simes J; Dalby A; Betriu A; Bode C; White HD; Hochman JS; Emanuelson H; Vahanian A; Sapp S; Stebbins A; Moliterno DJ; Califf RM
    Circulation; 2000 Oct; 102(15):1761-5. PubMed ID: 11023929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombolytic therapy for patients with prior percutaneous transluminal coronary angioplasty and subsequent acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries.
    Labinaz M; Sketch MH; Stebbins AL; DeFranco AC; Holmes DR; Kleiman NS; Betriu A; Rutsch WR; Vahanian A; Topol EJ; Califf RM
    Am J Cardiol; 1996 Dec; 78(12):1338-44. PubMed ID: 8970403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
    Mak KH; Moliterno DJ; Granger CB; Miller DP; White HD; Wilcox RG; Califf RM; Topol EJ
    J Am Coll Cardiol; 1997 Jul; 30(1):171-9. PubMed ID: 9207639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators.
    Simes RJ; Topol EJ; Holmes DR; White HD; Rutsch WR; Vahanian A; Simoons ML; Morris D; Betriu A; Califf RM
    Circulation; 1995 Apr; 91(7):1923-8. PubMed ID: 7895348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase.
    Kent DM; Hayward RA; Griffith JL; Vijan S; Beshansky JR; Califf RM; Selker HP
    Am J Med; 2002 Aug; 113(2):104-11. PubMed ID: 12133748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term mortality of patients with acute myocardial infarction in the United States and Canada: comparison of patients enrolled in Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I.
    Kaul P; Armstrong PW; Chang WC; Naylor CD; Granger CB; Lee KL; Peterson ED; Califf RM; Topol EJ; Mark DB
    Circulation; 2004 Sep; 110(13):1754-60. PubMed ID: 15381645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time to treatment with thrombolytic therapy: determinants and effect on short-term nonfatal outcomes of acute myocardial infarction. Canadian GUSTO Investigators. Global Utilization of Streptokinase and + PA for Occluded Coronary Arteries.
    Cox JL; Lee E; Langer A; Armstrong PW; Naylor CD
    CMAJ; 1997 Feb; 156(4):497-505. PubMed ID: 9054819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries. Results from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
    Van de Werf F; Topol EJ; Lee KL; Woodlief LH; Granger CB; Armstrong PW; Barbash GI; Hampton JR; Guerci A; Simes RJ
    JAMA; 1995 May 24-31; 273(20):1586-91. PubMed ID: 7745771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction.
    Mark DB; Hlatky MA; Califf RM; Naylor CD; Lee KL; Armstrong PW; Barbash G; White H; Simoons ML; Nelson CL
    N Engl J Med; 1995 May; 332(21):1418-24. PubMed ID: 7723799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombolysis and Q wave versus non-Q wave first acute myocardial infarction: a GUSTO-I substudy. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries Investigators.
    Barbagelata A; Califf RM; Sgarbossa EB; Goodman SG; Stebbins AL; Granger CB; Suarez LD; Borruel M; Gates K; Starr S; Wagner GS
    J Am Coll Cardiol; 1997 Mar; 29(4):770-7. PubMed ID: 9091523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-Q-wave versus Q-wave myocardial infarction after thrombolytic therapy: angiographic and prognostic insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries-I angiographic substudy. GUSTO-I Angiographic Investigators.
    Goodman SG; Langer A; Ross AM; Wildermann NM; Barbagelata A; Sgarbossa EB; Wagner GS; Granger CB; Califf RM; Topol EJ; Simoons ML; Armstrong PW
    Circulation; 1998 Feb; 97(5):444-50. PubMed ID: 9490238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of ST segment shift early after resolution of ST elevation in patients with myocardial infarction treated with thrombolytic therapy: the GUSTO-I ST Segment Monitoring Substudy.
    Langer A; Krucoff MW; Klootwijk P; Simoons ML; Granger CB; Barr A; Califf RM; Armstrong PW
    J Am Coll Cardiol; 1998 Mar; 31(4):783-9. PubMed ID: 9525547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient outcomes after fibrinolytic therapy for acute myocardial infarction at hospitals with and without coronary revascularization capability.
    Mehta RH; Criger DA; Granger CB; Pieper KK; Califf RM; Topol EJ; Bates ER
    J Am Coll Cardiol; 2002 Sep; 40(6):1034-40; discussion 1041-3. PubMed ID: 12354424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) trial. An observational study.
    Berger PB; Holmes DR; Stebbins AL; Bates ER; Califf RM; Topol EJ
    Circulation; 1997 Jul; 96(1):122-7. PubMed ID: 9236426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pitfalls in the economic evaluation of thrombolysis in myocardial infarction. The impact of national differences in the cost of thrombolytics and of differences in the efficacy across patient subgroups.
    Lorenzoni R; Pagano D; Mazzotta G; Rosen SD; Fattore G; De Caterina R; Gensini G
    Eur Heart J; 1998 Oct; 19(10):1518-24. PubMed ID: 9820990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO-1) trial on the use of thrombolytics in Germany. ALKK Study Group. Arbeitsgemeinschaft der Leitenden Kardiologischen Krankenhausärtze.
    Zahn R; Rustige J; Koch A; Schiele R; Burczyk U; Schuster S; Harmjanz D; Boppert D; Gottwik M; Neuhaus KL; Senges J
    Am J Cardiol; 1997 Nov; 80(10):1339-43. PubMed ID: 9388110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.